Journal of Hepatology

No abstract text is available yet for this article.

No abstract text is available yet for this article.

BACKGROUND AND AIMS: This study aimed to evaluate the ability of single nucleotide polymorphisms (SNPs) to refine hepatocellular carcinoma (HCC) risk stratification. METHODS: Six SNPs in PNPLA3, TM6SF2, HSD17B13, APOE, and MBOAT7 affecting lipid turnover and one variant involved in the Wnt-β-catenin pathway (WNT3A-WNT9A rs708113) were assessed in patients with alcohol-related and/or HCV-cured cirrhosis included in HCC surveillance programs (prospective CirVir and CIRRAL cohorts)...

BACKGROUND AND AIMS: The harmful impact of heavy alcohol recurrence has been confirmed in patients with alcohol-related cirrhosis although this is based on old studies. The drivers of long-term outcome still need to be clearly investigated. METHOD: All patients with biopsy-proven compensated alcohol-related cirrhosis included in the CIRRAL cohort (22 centers) were prospectively studied. Prognostic variables of survival and liver event-free survival were assessed using multivariable Cox models with stepwise selection...

BACKGROUND: The evidence for hepatobiliary tumour surveillance in patients with primary sclerosing cholangitis (PSC) is scarce. This study aimed to prospectively evaluate cholangiocarcinoma (CCA) surveillance with yearly magnetic resonance imaging including cholangiopancreatography (MRI/MRCP) in a nationwide cohort. METHODS: In total, 512 PS C patients from 11 Swedish hospitals were recruited. The study protocol included yearly clinical follow-ups, liver function tests and contrast-enhanced MRI/MRCP and carbohydrate antigen (CA) 19-9...

BACKGROUND: There are limited prospective data in a United States cohort of patients with type 2 diabetes mellitus (T2DM) specifically enrolled and systematically assessed for advanced fibrosis or cirrhosis due to nonalcoholic fatty liver disease (NAFLD). Therefore, we aimed to evaluate the prevalence of advanced fibrosis and cirrhosis in a prospectively recruited cohort of adults with T2DM. METHODS: This prospective study enrolled adults age ≥ 50 years with T2DM recruited from primary care or endocrinology clinics...

No abstract text is available yet for this article.

BACKGROUND & AIMS: The Liver Reporting and Data System (LI-RADS) version 2018 simplified the definition of threshold growth to '≥50% size increase in a mass in ≤6 months. However, the diagnostic value of threshold growth for HCC remained unclear. We evaluated the value of threshold growth, as defined by the LI-RADS v2018, in diagnosing HCCs. METHODS: Patients who underwent preoperative gadoxetate disodium-enhanced MRI because of the presence of LI-RADS category 2, 3, or 4 rather than category 5 on prior CT/MRI between January 2017 and December 2020 were retrospectively evaluated...

BACKGROUND & AIMS: We aim to evaluate the association between longitudinal changes in noninvasive tests for liver fibrosis such as FIB-4 over time and subsequent risk of hepatocellular carcinoma (HCC) and a composite endpoint of cirrhosis and HCC in patients with nonalcoholic fatty liver disease (NAFLD). METHODS: We conducted a retrospective cohort study of NAFLD patients seen in 130 Veterans Administration hospitals between 1/1/2004-12/31/2008 with follow-up through 12/31/2018...

No abstract text is available yet for this article.

No abstract text is available yet for this article.

Management of BTCs is rapidly evolving. Majority of patients are diagnosed with advanced disease, when chemotherapy with cisplatin and gemcitabine followed by second-line FOLFOX is the cornerstone of treatment in the absence of targetable alterations. Targeted therapies for tumours harbouring fibroblast growth factor receptor-2 (FGFR-2) fusions, isocitrate dehydrogenase-1 (IDH-1) mutations, BRAF V600E mutations, NTRK fusions and/or HER2 amplifications, among others, have brought precision medicine into the treatment landscape of advanced BTC...

No abstract text is available yet for this article.

BACKGROUND & AIMS: Currently available non-invasive tests, including FIB-4 and liver stiffness measurement (LSM by VCTE), are highly effective in excluding advanced fibrosis (AF) or cirrhosis yet their ability to rule in is moderate. Our objective was to develop and validate two new scores (Agile 4 and Agile 3+), combining LSM with routine clinical parameters to identify cirrhosis or AF, respectively, in those with NAFLD in specialized liver clinics, with optimized positive predictive value (PPV) and reduced number of cases with indeterminate results...

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

BACKGROUND AND AIMS: Acute liver failure (ALF) is a life-threatening disease characterised by high-grade inflammation and immunoparesis with a high incidence of death from sepsis. Here, we aimed to describe the metabolic dysregulation in ALF and determine whether systemic immune responses are modulated via the lysophosphatidylcholine(LPC)-autotaxin(ATX)-lysophosphatidylcholinic acid (LPA) pathway. METHODS: 96 ALF patients, 71 healthy controls (HC), 104 patients with cirrhosis and 31 septic patients were recruited...